There is considerable interest in the haemodynamic assessment of the newer bioprostheses. Although some in vitro haemodynamic information is available,' this is not easily extrapolated to the clinical situation. In addition the in vivo assessment of valve prostheses has usually been obtained intraoperatively2 3 This equation was applied to the maximum mitral diastolic flow velocity at each 10 ms interval throughout the diastolic time period and these results were averaged to obtain the mean mitral valve gradient. In addition we measured the mitral pressure half time, that is the time taken for the mitral diastolic flow velocity to fall to the equivalent of half the initial calculated peak pressure drop. In mitral stenosis this provided an assessment of the degree of mitral obstruction that was independent of cardiac Simpson, Reece, Houston, Hutton, Wheatley, Cobbe output24 and it has also been used to assess a small number of mitral valve prostheses. 16 We used continuous wave Doppler from the apical position to assess mitral regurgitation, which was indicated by high velocity systolic flow away from the transducer into the left atrial cavity. The pulsed wave mode, which allowed depth resolution of the Doppler signal, was then used to estimate the degree of mitral regurgitation, as previously reported,23 by measurement of the extent of flow into the left atrial cavity. Although it is not possible to provide precise quantification of the degree of mitral prosthetic regurgitation by this method it does allow identification of those patients with severe regurgitant lesions.
We measured aortic prosthetic flow velocity in the continuous wave mode from various precordial positions that have been used to assess aortic stenosis2-suprasternal notch, apex, subcostal, supraclavicular, and right parasternal in the right lateral decubitus position. The maximum systolic velocity with a clearly demarcated spectral signal was used to calculate the peak aortic valve gradient by the modified Bernoulli equation. The presence of aortic regurgitation was also determined from these precordial positions.
Tricuspid regurgitation was assessed from either the apical or left parasternal positions and when present it was used to estimate right ventricular systolic pressure derived from the gradient obtained across the tricuspid valve during systole. Assuming the absence of pulmonary valve disease the pulmonary artery systolic pressure could be determined.25 50-
--2-0. There was no significant difference in the peak aortic gradients across the three types of bioprostheses (Fig. 3) . Table 1 shows a comparison of all the mitral prostheses of various sizes. Only two patients had a 35mm mitral bioprosthesis (both Wessex porcine valves) and they were excluded. The 29 mm mitral bioprosthesis had a significantly longer pressure half , time than either the 31 mm or 33 mm sizes. There Hancock was no difference, however, in either the peak mitral pericardiol flow velocity or mean mitral valve gradient among / time (mean the three valve sizes. pected clinically in 12 of the 13 patients. mmHg (mean 21-9 mmHg) in the 21 patients with a competent bioprosthesis, and was 22 mm Hg, 33mm Hg, and 57mm Hg in the remaining three patients with mitral regurgitation.
Discussion
Doppler ultrasound has great potential as a noninvasive method of assessing bioprosthetic valve function. Although in vitro studies can provide data on the haemodynamic profile of various bioprostheses it is difficult to extrapolate from these results to the clinical situation.
The newer pericardial bioprostheses presented Doppler ultrasound assessment of bioprostheses less obstruction to flow than the porcine bioprostheses when they were studied in vitro22 and intraoperatively,3 though it is not certain whether this is of clinical relevance. The range of mean valve gradients for bioprostheses in the mitral position was quite narrow and gradients in all competent prostheses were acceptably low. We expected the valve gradients in the low profile Ionescu-Shiley pericardial valve to be lower than in the Wessex porcine bioprosthesis, but we did not expect them to be significantly lower than in the Hancock pericardial valve. Similarly the longer mitral pressure halftime in the Hancock pencardial prosthesis suggests that the in vivo obstructive characteristics ofthis valve differ from those that were established in vitro.
The mean mitral valve gradient was significantly lower for the low profile Ionescu-Shiley valve only at the 31 mm size and-not at-the 29mm size. The prolonged pressure halftime noted with the Hancock pericardial valve, however, occurred only at 29 mm and-not at 31 mm. Because the pressure half time relates more to the initial phase of diastole and the mean mitral gradient relates to the whole diastolic time period, the difference in pressure half time noted with the Hancock-pericardial valve could be explained by an increased restriction to flow during the first part of diastole, possibly as a result of less rapid leaflet opening, which may only be of relevance at the smaller valve size.
Similarly the low profile Ionescu-Shiley pericardial valve may be less obstructive throughout diastole and hence produce a significantly lower mean valve gradient with the 31 mm valve than Wessex or Hancock valves of similar size. This effect was also seen with the 29 mm size valves, but it was not significant. In vitro studies had not led us to expect these differences in mean valve gradient and mitral pressure half time, and such discrepancies indicate the complexity of the pressure flow relation across the mitral valve in vivo.
The slight reduction in the mitral pressure half time with the larger bioprostheses indicates a tendency to increased obstruction with smaller bioprostheses. There was no difference in the mean mitral valve gradients, however, which suggests that this may only have an effect at rest in the early diastolic period when valve flow is greater.
Although there was no overall difference between the three groups of aortic bioprostheses, the Wessex porcine valve, as expected, produced significantly higher peak aortic gradients than different valve types of similar size. formance. The question whether patients suspected of having less important mitral regurgitation will subsequently develop major leaflet tears will only be resolved by careful patient follow up and examination at reoperation. Aortic regurgitation was identified in 11 aortic bioprostheses, one of which had to be replaced because of leaflet tear. Although it is not possible to measure aortic regurgitation accurately by Doppler ultrasound, its identification in conjunction with clinical and other non-invasive assessment may predict the development of important prosthetic dysfunction at an early stage.
The estimation of right ventricular and therefore pulmonary artery systolic pressure in patients with tricuspid regurgitation is a useful adjunct to the assessment of bioprosthetic valve function. This was possible in several patients with mitral bioprostheses who had tricuspid regurgitation, presumably as a result of right ventricular dilatation associated with previous mitral valve disease. In all patients with a competent mitral bioprosthesis pulmonary pressures were satisfactory at rest, though they were significantly increased in a patient with mitral regurgitation.
This study has demonstrated the successful application of Doppler ultrasound techniques in a large series of patients with bioprosthetic valves. It allowed a comparison of the haemodynamic function of different bioprosthetic valves in vivo. Because it is both non-invasive and can be repeated it is likely to have a major impact on the continuing assessment of the newer types of bioprostheses. The ability to identify the presence of bioprosthetic regurgitation in these patients and to provide information on its severity in patients with mitral bioprostheses suggests that non-invasive assessment of developing bioprosthetic dysfunction may be possible.
